CTKB Cytek BioSciences Inc
85
$6.10
$0.08
(1.29%)
| Watchers | 85 |
| 52-Wk Low | $3.80 |
| 52-Wk High | $9.87 |
| Market Cap | $800.77M |
| Volume | 561,497.00 |
| 52-Wk High | $9.87 |
| 52-Wk Low | $3.80 |
Insider Sell: Cytek Biosciences Inc's (CTKB) Chief Technology Officer Ming Yan Sells 40,000 SharesGuruFocus • about 2 months ago
Related Stocks: CTKB...
Share to Feed
Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek...
Cytek Biosciences (NASDAQ:CTKB Get Free Report) had its target price cut by equities researchers at Piper Sandler from $11.00 to $10.00 in a report issued on Wednesday, Benzinga reports. The...
Cytek Wuxi Facility
Cytek's new 50,000-square-foot facility in Wuxi, China increases the company's manufacturing capacity to meet the growing worldwide demand for comprehensive cell...
Cytek Biosciences, Inc. (NASDAQ:CTKB Get Free Report)s stock price dropped 6.5% during mid-day trading on Wednesday after Piper Sandler lowered their price target on the stock from...
In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Cytek Biosciences (CTKB Research Report), with a price...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
In trading on Wednesday, shares of Cytek BioSciences Inc (CTKB) crossed below their 200 day moving average of 7.56, changing hands as low as 7.05 per share. Cytek BioSciences Inc shares...
Cytek Biosciences (NASDAQ:CTKB Free Report) had its price target increased by The Goldman Sachs Group from $9.00 to $10.00 in a research report sent to investors on Thursday, Benzinga...
Cytek Biosciences (NASDAQ:CTKB Free Report) had its price target boosted by The Goldman Sachs Group from $9.00 to $10.00 in a research report released on Thursday, Benzinga reports. The...